VRCA Earnings Prediction
The chart below shows how VRCA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VRCA sees a +13.74% change in stock price 10 days leading up to the earnings, and a -10.42% change 10 days following the report. On the earnings day itself, the stock moves by -4.32%. This data can give you a slight idea of what to expect for the next quarter's release.
VRCA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
5.18M
2744.51%
35.31%
Gross Margin
89.53%
254.29%
27.43%
Operating Margin
-293.72%
-95.40%
-39.58%
Net Margin
-331.97%
-94.50%
-37.53%
EPS
-0.37
-54.17%
-15.91%
No Data Available
VRCA Earnings Analysis
Verrica Pharmaceuticals Inc. Common Stock Corporation (VRCA.O) Earnings Conference Call
Positive
YCANTH recorded product revenue net of $4.9 million for the second quarter of 2024, showing growth in demand and expanded distribution footprint.
YCANTH has added specialty distribution partners such as Cencora and Vizient, enabling increased customer support and visibility for physicians.
Insurance companies covering approximately 98% of commercial lives with YCANTH coverage have formally published their allowables, driving confidence in payer coverage.
Verrica Pharmaceuticals settled a litigation with Dormer Laboratories, discontinuing the sale of compounded cantharidin products in the US market, enhancing patient access to safe and FDA-approved therapy.
Removal of compounded cantharidin from the marketplace is expected to have a positive impact on YCANTH demand.
Progress in advancing the treatment of common warts with YCANTH through an amended agreement with Torii Pharmaceutical for a global Phase 3 trial.
Amended agreement allows for joint funding of the trial, minimal impact on cash position, and potential marketing synergies with molluscum treatment promotion.
Exciting data released for lead pipeline candidate, VP-315, developed for the treatment of basal cell carcinoma.
Phase 2 study showed promising efficacy with a 51% complete histologic clearance rate and 86% overall reduction in tumor size across lesions treated.
VP-315 demonstrated safety and tolerability with no treatment-related Serious Adverse Events reported, positioning it as a potential first-line therapy alternative.
YCANTH revenue and gross product margins remained strong in the second quarter of 2024, bolstered by increased demand and cost efficiency in production processes.
Research and Development expenses decreased, while Selling, General and Administrative expenses increased due to commercial activity for YCANTH.
As of June 30, 2024, Verrica had aggregate cash and cash equivalents of $31.9 million, expected to be sufficient to fund operations into the first quarter of 2025, reflecting financial stability.
Non-GAAP net loss for the second quarter of 2024 was $14.4 million, compared to $9.4 million in the same period in 2023, demonstrating financial transparency and accountability.
Negative
- Despite progress in various areas, there was a significant increase in GAAP net loss from $11 million to $17.2 million year-over-year for the second quarter of 2024.
- The non-GAAP net loss also escalated from $9.4 million to $14.4 million year-over-year for the second quarter of 2024.
- The company's current cash and cash equivalents of $31.9 million may only be sufficient to fund operations into the first quarter of 2025, indicating potential financial challenges ahead.
VRCA FAQs
How does VRCA typically perform around its earnings report dates?
Is Verrica Pharmaceuticals, Inc. (VRCA) Q2 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
VRCA Earning Call Sentiment
Verrica Pharmaceuticals, Inc. (VRCA) Q2 2024 Earnings Call Transcript
1.0x
00:00
00:00
VRCA.O
-1.71%Positive
The earnings call reveals operational challenges and economic factors impacting YCANTH adoption, with no shareholder return plan. Despite strong gross margins, the net loss widened, and there is uncertainty in guidance. The Q&A session showed management's reluctance to provide clear guidance, creating further uncertainty. The financial performance was disappointing, with increased expenses and a larger net loss. The lack of guidance and shareholder returns, coupled with operational challenges, suggests a negative sentiment, likely leading to a stock price decrease of -2% to -8%.
